Exploring drug repurposing as a therapeutic strategy for non-alcoholic fatty liver disease (NAFLD): identification of potential targets and pathways.
Gastroenterology and hepatology from bed to bench. · 01.01.2025 · 18 (2) · 230-245
DOI: 10.22037/ghfbb.v18i2.3071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastroenterology and hepatology from bed to bench., erschienen am 01.01.2025. Verfasst von Yalda Khazaei-Poul und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
This study investigates drug repurposing as a viable approach identifying existing pharmacological agents that could be applied to NAFLD management.
Background
Non-alcoholic fatty liver disease (NAFLD) is a prevalent and complex liver condition affecting approximately 25% of the global population, with significant links to metabolic disorders such as obesity and type 2 diabetes. Despite its high burden, no approved therapies currently exist for NAFLD, underscoring the need for effective treatments.
Methods
We utilized two publicly available datasets (GSE126848 and GSE130970) to identify differentially expressed genes (DEGs) and constructed a protein-protein interaction (PPI) network using Cytoscape. Hub and bottleneck (H&B) genes were identified and further analyzed for pathway enrichment using DAVID and KEGG. Drug candidates were identified through the Connectivity Map (CMap) platform, focusing on compounds with counter-gene signatures.
Results
Pathway analysis highlighted critical pathways involved in NAFLD pathogenesis, including the AGE-RAGE and Rap1 signaling pathways. Several promising repurposed drugs, such as WYE-354 and Triciribine, were identified, targeting key mechanisms like lipid metabolism and inflammation.
Conclusion
This study suggests that drug repurposing may accelerate the development of effective NAFLD therapies, although further clinical validation is needed to confirm the therapeutic potential of these findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Genomics Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran.
- Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zitieren
APA
Khazaei-Poul, Y., Ziayifard, S., Rashtchian, A., Pyriae, A., & Ziai, S. A. (2025). Exploring drug repurposing as a therapeutic strategy for non-alcoholic fatty liver disease (NAFLD): identification of potential targets and pathways. Gastroenterology and hepatology from bed to bench., 18(2), 230-245. https://doi.org/10.22037/ghfbb.v18i2.3071
Vancouver
Khazaei-Poul Y, Ziayifard S, Rashtchian A, Pyriae A, Ziai SA. Exploring drug repurposing as a therapeutic strategy for non-alcoholic fatty liver disease (NAFLD): identification of potential targets and pathways. Gastroenterology and hepatology from bed to bench.. 2025;18(2):230-245. doi:10.22037/ghfbb.v18i2.3071
BibTeX
@article{KhazaeiPoul2025,
author = {Khazaei-Poul, Yalda and Ziayifard, Sara and Rashtchian, Ava and Pyriae, Abbas and Ziai, Seyed Ali},
title = {Exploring drug repurposing as a therapeutic strategy for non-alcoholic fatty liver disease (NAFLD): identification of potential targets and pathways},
journal = {Gastroenterology and hepatology from bed to bench.},
year = {2025},
volume = {18},
number = {2},
pages = {230--245},
doi = {10.22037/ghfbb.v18i2.3071}
}
EUVIMED